To gain insights into the progression of EMT during resistance formation to EGFR-TKI, we employed a stepwise adaptation approach osimertinib, which is currently the standard of care for NSCLC patients with tumors harboring EGFR-activating mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.